Lisinopril Tablets USP, 20 mg, 1000-count bottles, Rx Only, Manufactured by: Wockhardt Limited, Mumbai, India; Distributed by: Wockhardt USA LLC, 20 Waterview Blvd, Parsippany, NJ 07054 USA, UPC 3 64679 94106 5, NDC 64679-941-06.

Recall Insight

This FDA Drug action (record #D-1347-2015) was formally reported on August 26, 2015, with the manufacturer initiating the action on July 29, 2015. It is classified under Moderate severity (Class II), with a current status of Terminated. Wockhardt Usa Inc. is listed as the recalling firm, operating out of Parsippany, NJ. Federal records indicate 3378 bottles units are affected.

The documented reason for this recall is: CGMP Deviations: An FDA inspection identified inadequate investigations of past market complaints. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 11 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.